Navigation Links
Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
Date:8/29/2007

-Trial Initiation Triggers $2.0 Million Milestone Payment from Roche-

MONTVALE, N.J., Aug. 29 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced the dosing of the first subject in the single ascending dose (SAD) study of its Phase 1 clinical program of R4996/MEM 63908, a partial agonist of the nicotinic alpha-7 receptor. Compounds acting on this receptor could be beneficial in the treatment of Alzheimer's disease and schizophrenia, as well as other psychiatric and neurological disorders.

"We are excited to advance R4996/MEM 63908 into clinical studies and further explore the potential of nicotinic alpha-7 receptor agonists in multiple CNS indications," said Stephen Murray, M.D., Ph.D., Chief Medical Officer. "Together with our partner Roche, we have built a leading position in the development of nicotinic alpha-7 receptor agonists, and the advancement of R4996/MEM 63908 into the clinic reflects our continued progress with our Nicotinic Alpha-7 Agonist Program."

The randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability and pharmacokinetics of ascending doses of R4996/MEM 63908 in healthy adult male volunteers. The study will be conducted in Montreal, Canada under a Clinical Trial Application that Memory Pharmaceuticals filed with Health Canada. As part of the Phase 1 clinical program for R4996/MEM 63908, the Company is planning to conduct a food interaction study in healthy adult male volunteers and a randomized, placebo- controlled single dose study in elderly male and female volunteers. The Company expects to complete the SAD study in the first quarter of 2008.

R4996/MEM 63908 is being developed as part of the Company's nic
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. New Study Suggests no Significant Impairment in Middle-of-the-Night Balance, Mobility or Memory in Older Adults Using Ramelteon
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... 25 AMPAC Fine Chemicals LLC (AFC)...sdaq: APFC ) announced today that it received the...ward at the Annual Statewide Environmental Summit,...hnology Association (CMTA), the Industrial Environ... Council of California (CICC) held in San Diego. ...
(Date:11/25/2009)...ewswire/ -- Reportlinker.com announces that a new ...ue: ,, Mammography Equipment - A Global Marke.../p0164330/Mammography-Equipment---A-Global-Market-... cancer in industrialized as well as developing na...the mammography market. Globally, escalating aware...
(Date:11/25/2009)...PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: ...ping products for minimally disruptive surgical tr...ll host a conference call on Monday, November 30, ...nce call will focus on current issues relative to ...include comments from management followed by a sho...
Breaking Medicine Technology:AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3NuVasive Announces Conference Call and Webcast Regarding Reimbursement 4ViroPharma to Release 2009 Third Quarter Financial Results on October 28 2009 59581 1ViroPharma to Release 2009 Third Quarter Financial Results on October 28 2009 59581 2Consecos Four Major Offices Wrap Up Record Breaking United Way Campaign 59579 1Consecos Four Major Offices Wrap Up Record Breaking United Way Campaign 59579 2BioMed Realty Trust to Report 2009 Third Quarter Results 59577 1BioMed Realty Trust to Report 2009 Third Quarter Results 59577 2
(Date:11/27/2009)... Biotech firm Replikins Ltd. today issued its la...c data. It shows that the lethality of the virus ... the virus,s current outbreak in the spring of 200...(s.d. 0.1). The H1N1 infectivity count, however, r...n (PRWEB) November 27, 2009 -- Biotech firm Replik...
(Date:11/27/2009)...UR-SEINE, France, Nov. 27 Team Gar...cling team dedicated to ethical sporting and devel...nounced today that it will become Team Garmin-Tran...s a new sponsor of the team. Transitions Optical i...wear, offering the most advanced photochromic tech...
(Date:11/27/2009)...unprecedented medical, economic burdens, study pre...s) -- The number of people with diabetes in the Un... years, a new study predicts. , That would brin...ith the disease, up from 23.7 million today. , ,...h diabetes will triple, the study also warns, risi...
(Date:11/27/2009)... Specialist manufacturers who use medical load c...lions of dollars by bringing in technology partner...umbers of pro-active medical manufacturers are cal...tage of their projects, ensuring that progress wil...or potentially outdated technology. , ...
(Date:11/26/2009)... the number of Americans living with diabetes will...09 to 44.1 million in 2034. Over the same period, ...om $113 billion to $336 billion, even with no incr...ed at the University of Chicago report in the Dece...hose with diabetes covered by Medicare will rise f...
Breaking Medicine News(10 mins):Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3
...rgery during the last 35 years at Johns Hopkins Un...// Charles J. Yeo, M.D., Samuel D. Gross Professor... of Thomas Jefferson University and Thomas Jeffers...ut of medicine may believe, major pancreatic cance...
...as revealed that variants of a sugar, is found to ... studies are still in ithe nascent stages, these f...manage Alzheimers and even offset the onslaught. ...isease. A treatment based on this, Scyllo-inositol...
...intestinal surgery, including stomach reduction fo...nt vitamin A deficiency//. The results of the stud...hthalmology. The researchers base their findi... patients had a family or personal history of eye ...
...o the long time mystery surrounding obesity patien...emory loss//. New Saint Louis University research ...eptin is a hormone secreted by fat cells that tell...d associate research professor in the division of ...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: